

Olivier Rascol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3070774/publications.pdf>

Version: 2024-02-01

252
papers

29,837
citations

7096

78
h-index

5255

165
g-index

278
all docs

278
docs citations

278
times ranked

21511
citing authors

#	ARTICLE	IF	CITATIONS
1	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	3.9	4,796
2	Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. <i>The Movement Disorder Society Task Force on rating scales for Parkinson's disease. Movement Disorders</i> , 2004, 19, 1020-1028.	3.9	1,739
3	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. <i>New England Journal of Medicine</i> , 2000, 342, 1484-1491.	27.0	1,467
4	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	3.9	1,097
5	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	27.0	830
6	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003, 54, 93-101.	5.3	820
7	Depression rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2007, 22, 1077-1092.	3.9	583
8	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Movement Disorders</i> , 2004, 19, 1391-1402.	3.9	481
9	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, S2-41.	3.9	479
10	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 573-580.	10.2	476
11	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 264-274.	10.2	426
12	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. <i>Brain</i> , 2010, 133, 3423-3433.	7.6	374
13	Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1064-1071.	3.9	374
14	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. <i>Lancet</i> , The, 2014, 383, 1138-1146.	13.7	368
15	Priorities in Parkinson's disease research. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 377-393.	46.4	364
16	Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. <i>Lancet Neurology</i> , The, 2007, 6, 513-520.	10.2	359
17	Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. <i>Annals of Neurology</i> , 2001, 50, 718-729.	5.3	345
18	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , 2016, 98, 500-513.	6.2	333

#	ARTICLE	IF	CITATIONS
19	Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2004, 19, 997-1005.	3.9	331
20	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	5.3	330
21	LRRK2 in Parkinson disease: challenges of clinical trials. <i>Nature Reviews Neurology</i> , 2020, 16, 97-107.	10.1	281
22	How much phenotypic variation can be attributed to parkingenotype?. <i>Annals of Neurology</i> , 2003, 54, 176-185.	5.3	271
23	Treatment interventions for Parkinson's disease: an evidence based assessment. <i>Lancet, The</i> , 2002, 359, 1589-1598.	13.7	266
24	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. <i>Movement Disorders</i> , 1998, 13, 39-45.	3.9	262
25	Chronic pain in Parkinson's disease: The crossâ€sectional French DoPaMiP survey. <i>Movement Disorders</i> , 2008, 23, 1361-1369.	3.9	257
26	Limitations of current Parkinson's disease therapy. <i>Annals of Neurology</i> , 2003, 53, S3-S15.	5.3	250
27	Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. <i>Movement Disorders</i> , 2007, 22, 179-186.	3.9	249
28	Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 884.	9.0	241
29	Supplementary and Primary Sensory Motor Area Activity in Parkinson's Disease. <i>Archives of Neurology</i> , 1992, 49, 144.	4.5	222
30	Tenâ€year followâ€up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	3.9	221
31	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurology, The</i> , 2016, 15, 154-165.	10.2	219
32	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 2704-2716.	3.9	214
33	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	3.9	205
34	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2018, 17, 749-759.	10.2	203
35	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 805-822.	3.9	193
36	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology, The</i> , 2011, 10, 415-423.	10.2	192

#	ARTICLE	IF	CITATIONS
37	Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends in Neurosciences, 2000, 23, S117-S126.	8.6	185
38	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nature Reviews Drug Discovery, 2018, 17, 804-822.	46.4	178
39	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurology, The, 2013, 12, 747-755.	10.2	175
40	Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology, 2018, 91, e189-e201.	1.1	175
41	A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathologica, 1999, 98, 62-77.	7.7	174
42	Mapping of Spinocerebellar Ataxia 13 to Chromosome 19q13.3-q13.4 in a Family with Autosomal Dominant Cerebellar Ataxia and Mental Retardation. American Journal of Human Genetics, 2000, 67, 229-235.	6.2	166
43	Milestones in Parkinson's disease therapeutics. Movement Disorders, 2011, 26, 1072-1082.	3.9	162
44	Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study). Clinical Neuropharmacology, 2004, 27, 58-62.	0.7	161
45	Neural Substrate for the Effects of Passive Training on Sensorimotor Cortical Representation: A Study with Functional Magnetic Resonance Imaging in Healthy Subjects. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 478-484.	4.3	153
46	Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurology, The, 2012, 11, 589-596.	10.2	150
47	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 197.	9.0	146
48	Within-Session and Between-Session Reproducibility of Cerebral Sensorimotor Activation: A Test-Retest Effect Evidenced with Functional Magnetic Resonance Imaging. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 592-607.	4.3	145
49	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. Movement Disorders, 1998, 13, 46-51.	3.9	135
50	Prediction of cognition in Parkinson's disease with a clinical genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
51	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	3.6	128
52	Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France. Movement Disorders, 2011, 26, 2226-2231.	3.9	122
53	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Movement Disorders, 2013, 28, 1838-1846.	3.9	122
54	Withdrawing amantadine in dyskinetic patients with Parkinson disease. Neurology, 2014, 82, 300-307.	1.1	122

#	ARTICLE	IF	CITATIONS
55	Orthostatic Hypotension in Patients with Parkinson's Disease. <i>Drugs and Aging</i> , 2001, 18, 495-505.	2.7	115
56	Placebo influences on dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 700-707.	3.9	111
57	A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 1373-1380.	3.9	111
58	A Single Dose of the Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output: Double-Blind, Placebo-Controlled, fMRI Study in Healthy Subjects. <i>NeuroImage</i> , 2002, 15, 26-36.	4.2	107
59	Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. <i>Lancet Neurology</i> , The, 2018, 17, 223-231.	10.2	105
60	Subthalamic Nucleus Stimulation Reduces Abnormal Motor Cortical Overactivity in Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1307-13.	4.5	104
61	Object naming and action-verb generation in Parkinson's disease: A fMRI study. <i>Cortex</i> , 2009, 45, 960-971.	2.4	103
62	Prolonged-release oxycodone/naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 1161-1170.	10.2	102
63	Volume and iron content in basal ganglia and thalamus. <i>Human Brain Mapping</i> , 2009, 30, 2667-2675.	3.6	98
64	Antivertigo Medications and Drug-Induced Vertigo. <i>Drugs</i> , 1995, 50, 777-791.	10.9	96
65	Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease. <i>CNS Drugs</i> , 2010, 24, 941-968.	5.9	96
66	¹²³ I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. <i>Movement Disorders</i> , 2009, 24, S732-41.	3.9	95
67	New treatments for levodopa-induced motor complications. <i>Movement Disorders</i> , 2015, 30, 1451-1460.	3.9	95
68	Iron as a therapeutic target for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 568-574.	3.9	94
69	Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 947-956.	2.2	93
70	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 1131-1142.	3.9	90
71	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 145-152.	10.2	90
72	Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2542-2549.	3.9	87

#	ARTICLE	IF	CITATIONS
73	Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. <i>Movement Disorders</i> , 2016, 31, 325-334.	3.9	87
74	Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 181-183.	0.7	85
75	Prevalence and Pharmacological Factors Associated With Impulse-Control Disorder Symptoms in Patients With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 261-265.	0.7	85
76	Effect of Side and Rate of Stimulation on Cerebral Blood Flow Changes in Motor Areas during Finger Movements in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 639-645.	4.3	83
77	Parkinson's disease and local atrophy in subcortical nuclei: insight from shape analysis. <i>Neurobiology of Aging</i> , 2015, 36, 424-433.	3.1	81
78	Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 1491.	9.0	80
79	Unmasking levodopa resistance in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1602-1609.	3.9	80
80	A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 852-861.	2.0	79
81	Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. <i>Movement Disorders</i> , 1994, 9, 437-440.	3.9	78
82	MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2018, 33, 600-608.	3.9	77
83	Which dyskinesia scale best detects treatment response?. <i>Movement Disorders</i> , 2013, 28, 341-346.	3.9	76
84	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. <i>Movement Disorders</i> , 2018, 33, 1528-1539.	3.9	73
85	Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. <i>NeuroImage</i> , 2005, 27, 299-313.	4.2	72
86	Cerebral Functional Magnetic Resonance Imaging Activation Modulated by a Single Dose of the Monoamine Neurotransmission Enhancers Fluoxetine and Fenzolone during Hand Sensorimotor Tasks. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 1365-1375.	4.3	70
87	Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 284-288.	3.9	68
88	Amantadine in the treatment of Parkinson's disease and other movement disorders. <i>Lancet Neurology</i> , The, 2021, 20, 1048-1056.	10.2	67
89	Parkinson's disease and weight loss: A study with anthropometric and nutritional assessment. <i>Clinical Autonomic Research</i> , 1992, 2, 153-157.	2.5	66
90	Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2007, 22, 1138-1144.	3.9	66

#	ARTICLE	IF	CITATIONS
91	The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. <i>Brain</i> , 2011, 134, 856-862.	7.6	66
92	The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. <i>Movement Disorders</i> , 2014, 29, 1074-1079.	3.9	66
93	Multiple System Atrophy: Recent Developments and Future Perspectives. <i>Movement Disorders</i> , 2019, 34, 1629-1642.	3.9	65
94	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. <i>Movement Disorders</i> , 2010, 25, 896-905.	3.9	63
95	Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 548-552.	2.2	62
96	Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. <i>Movement Disorders</i> , 2006, 21, 2110-2115.	3.9	61
97	Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia. <i>Journal of Neural Transmission</i> , 2018, 125, 1237-1250.	2.8	61
98	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.	3.9	59
99	Falls in ambulatory non-demented patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 1447-1455.	2.8	55
100	Factors related to orthostatic hypotension in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 501-505.	2.2	54
101	A Phase 1 Randomized Trial of Specific Active α -Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. <i>Movement Disorders</i> , 2020, 35, 1957-1965.	3.9	53
102	The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. <i>Movement Disorders</i> , 2011, 26, 1985-1992.	3.9	52
103	Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release. <i>Parkinson's Disease</i> , 2014, 2014, 1-8.	1.1	51
104	Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. <i>Brain</i> , 2015, 138, 1271-1283.	7.6	51
105	Influence of Age, Circadian and Homeostatic Processes on Inhibitory Motor Control: A Go/Nogo Task Study. <i>PLoS ONE</i> , 2012, 7, e39410.	2.5	51
106	Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study. <i>Movement Disorders</i> , 2003, 18, 418-425.	3.9	50
107	Perampanel in Parkinson Disease Fluctuations. <i>Clinical Neuropharmacology</i> , 2012, 35, 15-20.	0.7	50
108	Methylphenidate modulates cerebral post-stroke reorganization. <i>NeuroImage</i> , 2006, 33, 913-922.	4.2	49

#	ARTICLE	IF	CITATIONS
109	Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. <i>Neurobiology of Disease</i> , 2020, 139, 104813.	4.4	49
110	Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. <i>Neuropsychologia</i> , 2002, 40, 1815-1821.	1.6	47
111	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 898.e1-898.e7.	2.5	46
112	Dyskinesia: L-Dopa-Induced and Tardive Dyskinesia. <i>Clinical Neuropharmacology</i> , 2001, 24, 313-323.	0.7	45
113	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1489-1496.	3.9	45
114	Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. <i>Journal of Neurology</i> , 2001, 248, 426-427.	3.6	44
115	Adverse Drug Reactions to Selegiline [colon] A Review of the French Pharmacovigilance Database. <i>Clinical Neuropharmacology</i> , 2000, 23, 271-275.	0.7	43
116	Skin cancer and Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 139-148.	3.9	43
117	L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. <i>European Journal of Neurology</i> , 2017, 24, 1532-1538.	3.3	43
118	Rotigotine transdermal delivery for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 677-691.	1.8	41
119	Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1323-1329.	2.2	40
120	Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. <i>CNS Drugs</i> , 2016, 30, 703-717.	5.9	40
121	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. <i>Neurology</i> , 2018, 90, e1849-e1857.	1.1	40
122	??2-Adrenoceptor Antagonists. <i>CNS Drugs</i> , 1998, 10, 189-207.	5.9	39
123	Clinical Features and Disease Haplotypes of Individuals With the N279K tau Gene Mutation. <i>Archives of Neurology</i> , 2002, 59, 943.	4.5	39
124	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 79-85.	2.2	39
125	Rationale for delayed-start study of pramipexole in Parkinson's disease: The PROUD study. <i>Movement Disorders</i> , 2010, 25, 1627-1632.	3.9	38
126	Pardoprinox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011, 26, 1464-1476.	3.9	38

#	ARTICLE	IF	CITATIONS
127	Clinical and economic analysis of spa therapy in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 578-584.	3.9	37
128	Suggestive association between <i>OPRM1</i> and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1878-1886.	3.9	37
129	Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. <i>Movement Disorders</i> , 1998, 13, 673-676.	3.9	36
130	Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2326-2332.	3.9	36
131	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 351-360.	2.4	35
132	Young-Onset Parkinson Disease With and Without Parkin Gene Mutations. <i>Archives of Neurology</i> , 2003, 60, 713.	4.5	35
133	Hereditary ferritinopathy. <i>Journal of the Neurological Sciences</i> , 2003, 207, 110-111.	0.6	34
134	Confinement and Sleep Deprivation Effects on Propensity to Take Risks. <i>Aviation, Space, and Environmental Medicine</i> , 2009, 80, 73-80.	0.5	34
135	Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double-blind, placebo-controlled, crossover trial. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 558-570.	1.9	34
136	Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations. <i>Archives of Neurology</i> , 2008, 65, 577.	4.5	32
137	Double-blind study of pargolprunox, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.	3.9	32
138	Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: An important but still unmet need. <i>Movement Disorders</i> , 2006, 21, 1059-1061.	3.9	31
139	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <i>Movement Disorder Society</i> Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.5	31
140	A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 336-341.	3.9	30
141	Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study. <i>Movement Disorders</i> , 2004, 19, 83-90.	3.9	30
142	Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-Undertreated Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 174-181.	0.7	30
143	Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study. <i>Movement Disorders</i> , 2019, 34, 1663-1671.	3.9	30
144	Drugs Associated With Restless Legs Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 824-827.	1.4	29

#	ARTICLE	IF	CITATIONS
145	An original pharmacoepidemiologicalâ€“pharmacodynamic method: application to antipsychoticâ€“induced movement disorders. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 612-622.	2.4	29
146	Safety and Tolerability of Active Immunotherapy Targeting Î±-Synuclein with PD03A in Patients with Early Parkinsonâ€™s Disease: A Randomized, Placebo-Controlled, Phase 1 Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1079-1089.	2.8	29
147	Rasagiline in the pharmacotherapy of Parkinsonâ€™s disease â€“ a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2061-2075.	1.8	28
148	Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies. <i>Neurobiology of Disease</i> , 2014, 67, 133-139.	4.4	28
149	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. <i>Movement Disorders</i> , 2016, 31, 1049-1054.	3.9	28
150	A proofâ€“ofâ€“concept, randomized, placeboâ€“controlled, multiple crossâ€“overs (nâ€“ofâ€“1) study of naftazone in Parkinsonâ€™s disease. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 557-564.	1.9	27
151	Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (â€“en-of-1â€“) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 416-421.	2.2	27
152	Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 4-10.	2.2	26
153	Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study. <i>Movement Disorders</i> , 2021, 36, 750-757.	3.9	26
154	Safety of rasagiline for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 633-643.	2.4	25
155	The safety and efficacy of safinamide mesylate for the treatment of Parkinsonâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 245-258.	2.8	25
156	Safety Profile of Opicapone in the Management of Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 733-740.	2.8	25
157	Assessment of the Scopa-Aut questionnaire in multiple system atrophy: Relation to UMSARS scores and progression over time. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 612-615.	2.2	24
158	Current Concepts in the Treatment of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 6-16.	1.5	24
159	A study of tolerance to apomorphine. <i>British Journal of Pharmacology</i> , 1996, 117, 781-786.	5.4	23
160	A Pharmacoeconomic Evaluation of Botulinum Toxin in the Treatment of Spasmodic Torticollis. <i>Clinical Neuropharmacology</i> , 2000, 23, 203-207.	0.7	23
161	Do Parkinsonâ€™s disease patients disclose their adverse events spontaneously?. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 857-865.	1.9	23
162	Atropinic (Anticholinergic) Burden in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 632-636.	3.9	23

#	ARTICLE	IF	CITATIONS
163	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.1	23
164	How to diagnose parkinsonian central pain?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 50-53.	2.2	22
165	A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 128-133.	2.2	22
166	Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo-controlled, randomized, double-blind, crossover study. <i>Movement Disorders</i> , 2010, 25, 368-376.	3.9	21
167	Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2009, 279, 76-79.	0.6	20
168	Rotigotine transdermal patch for the treatment of Parkinson's Disease. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 81-95.	1.9	20
169	A Pilot Study of Stiripentol, a new Anticonvulsant Drug, in Complex Partial Seizures Uncontrolled by Carbamazepine. <i>Clinical Neuropharmacology</i> , 1989, 12, 119-123.	0.7	19
170	Dopaminergics and fibrotic valvular heart disease: Further considerations. <i>Movement Disorders</i> , 2004, 19, 1524-1525.	3.9	19
171	Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database. <i>Movement Disorders</i> , 2010, 25, 1876-1880.	3.9	19
172	Pramipexole for the treatment of early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 925-935.	2.8	19
173	Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , 2016, 7, 27.	2.4	19
174	Skin cancers and precancerous lesions in Parkinson's disease patients. <i>Movement Disorders</i> , 2007, 22, 1471-1475.	3.9	18
175	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. <i>Movement Disorders</i> , 2012, 27, 1683-1685.	3.9	18
176	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 479-491.	1.5	18
177	Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 199-203.	2.2	18
178	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. <i>Movement Disorders</i> , 2021, 36, 1704-1711.	3.9	18
179	Glial Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]-PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	3.9	18
180	COMT Inhibitors in the Management of Parkinson's Disease. <i>CNS Drugs</i> , 2022, 36, 261-282.	5.9	18

#	ARTICLE	IF	CITATIONS
181	Î±2-Adrenergic Sensitivity in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1989, 12, 138-144.	0.7	17
182	Contrasting Changes in Cortical Activation Induced by Acute High-Frequency Stimulation within the Globus Pallidus in Parkinson's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 235-243.	4.3	17
183	Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson's disease. <i>Neurophysiologie Clinique</i> , 2018, 48, 103-110.	2.2	17
184	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	2.2	17
185	Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1019-1033.	2.8	17
186	A Randomized, Double-Blind, Controlled Phase II Study of Folicurax in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1088-1093.	3.9	17
187	LRP10 in Î±-synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1034.	10.2	16
188	Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 2101-2106.	3.9	16
189	Broad white matter impairment in multiple system atrophy. <i>Human Brain Mapping</i> , 2021, 42, 357-366.	3.6	16
190	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. <i>Movement Disorders</i> , 2021, 36, 449-459.	3.9	16
191	On-Demand Therapy for OFF Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2244-2253.	3.9	16
192	Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. <i>Movement Disorders</i> , 2004, 19, 1006-1011.	3.9	15
193	Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 51-56.	2.2	15
194	Brain 5-HT _{1A} Receptor Binding in Multiple System Atrophy: An [¹⁸ F]-MPPF PET Study. <i>Movement Disorders</i> , 2021, 36, 246-251.	3.9	15
195	Cardiovascular effects of central injection of acetylcholine in anaesthetized dogs: a role for vasopressin release. <i>British Journal of Pharmacology</i> , 1990, 100, 471-476.	5.4	14
196	Pergolide. <i>Clinical Neuropharmacology</i> , 2005, 28, 120-125.	0.7	14
197	Assessment of quality of life with the multiple system atrophy health-related quality of life scale. <i>Movement Disorders</i> , 2012, 27, 1574-1577.	3.9	14
198	Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, S75-S83.	2.8	14

#	ARTICLE	IF	CITATIONS
199	Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2000, 13, 431-436.	3.6	13
200	Migraine Attacks Induced by Subcutaneous Apomorphine in Two Migrainous Parkinsonian Patients. <i>Clinical Neuropharmacology</i> , 1990, 13, 264-267.	0.7	12
201	New Directions in the Drug Treatment of Parkinson's Disease. <i>Drugs and Aging</i> , 1996, 9, 169-184.	2.7	12
202	A Study of Dopaminergic Sensitivity in Parkinson's Disease: Comparison in "De Novo" and Levodopa-Treated Patients. <i>Clinical Neuropharmacology</i> , 1996, 19, 420-427.	0.7	11
203	Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 99-103.	1.9	11
204	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 649-659.	2.8	11
205	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. <i>Movement Disorders</i> , 2017, 32, 1356-1364.	3.9	11
206	LRP10 in α -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1033-1034.	10.2	11
207	Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study. <i>Drugs and Aging</i> , 2020, 37, 215-223.	2.7	11
208	β -Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case-Control Study. <i>CNS Drugs</i> , 2020, 34, 763-772.	5.9	11
209	Monoamine oxidase inhibitors "is it time to up the TEMPO?". <i>Lancet Neurology</i> , The, 2003, 2, 142-143.	10.2	10
210	Serotonin reuptake inhibitors for depression in PD. <i>Nature Reviews Neurology</i> , 2012, 8, 365-366.	10.1	10
211	Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 635-645.	1.8	10
212	Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 30-33.	2.2	10
213	Lack of Correlation Between Plasma Levels of Amitriptyline (and Nortriptyline) and Clinical Improvement of Chronic Pain of Peripheral Neurologic Origin. <i>Clinical Neuropharmacology</i> , 1987, 10, 560-564.	0.7	9
214	A Cross-Sectional Study on Drug Use in Multiple System Atrophy. <i>CNS Drugs</i> , 2014, 28, 483-490.	5.9	9
215	Tamoxifen and the risk of Parkinsonism: a case/non-case study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1181-1184.	1.9	9
216	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease "Rating Scale (QUIP-RS). <i>Parkinsonism and Related Disorders</i> , 2019, 63, 117-123.	2.2	9

#	ARTICLE	IF	CITATIONS
217	Involvement of a pertussis toxin-sensitive G α protein in the pharmacological properties of septo-hippocampal neurones. <i>British Journal of Pharmacology</i> , 1989, 96, 956-960.	5.4	8
218	Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2221-2230.	1.8	8
219	The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1309-1323.	2.8	8
220	Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. <i>Parkinsonism and Related Disorders</i> , 2022, 96, 65-73.	2.2	8
221	Extended-release carbidopa-levodopa in Parkinson's disease. <i>Lancet Neurology</i> , The, 2013, 12, 325-326.	10.2	7
222	Distinctive Features of NREM Parasomnia Behaviors in Parkinson's Disease and Multiple System Atrophy. <i>PLoS ONE</i> , 2015, 10, e0120973.	2.5	7
223	Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 791-796.	2.5	7
224	Reversible myoclonus-ataxia encephalitis related to anti-mGluR1 autoantibodies. <i>Movement Disorders</i> , 2019, 34, 438-439.	3.9	7
225	Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. <i>Journal of Parkinson's Disease</i> , 2021, 11, 421-429.	2.8	7
226	Dopamine agonists. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 73-92.	1.8	6
227	The "Long and Winding Road" of the Disease-Modifying Effects of Levodopa Has Not Ended Yet. <i>Movement Disorders</i> , 2020, 35, 397-399.	3.9	6
228	Therapeutic strategies for Parkinson's disease: promising agents in early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1249-1267.	4.1	6
229	Personality dimensions of patients can change during the course of parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0245142.	2.5	5
230	Thought disorders among non-demented outpatients with Parkinson's disease: prevalence and associated factors. <i>Journal of Neural Transmission</i> , 2010, 117, 1183-1188.	2.8	4
231	Jejunal levodopa infusion in Parkinson's disease. <i>Lancet Neurology</i> , The, 2014, 13, 128-129.	10.2	4
232	Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 226-234.	2.2	4
233	Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson's Disease Patients (PSYCHO-STIM). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1-9.	2.8	4
234	The management of patients with early Parkinson's disease. <i>Advances in Neurology</i> , 2003, 91, 203-11.	0.8	4

#	ARTICLE	IF	CITATIONS
235	Adrenal Catecholamine Concentration After Domperidone. <i>Clinical Neuropharmacology</i> , 1987, 10, 479-481.	0.7	3
236	Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 509-522.	0.8	3
237	Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort. <i>Journal of Neural Transmission</i> , 2020, 127, 1607-1617.	2.8	3
238	Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 789-793.	2.8	2
239	CVT-301 for Parkinson's disease: dose and effect size issues. <i>Lancet Neurology</i> , The, 2019, 18, 128-130.	10.2	2
240	Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery. <i>Neurology</i> , 2021, 97, e1994-e2006.	1.1	2
241	Orthostatic hypotension in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2013, 3, 363-377.	2.2	1
242	Can a new trial end controversy over when to use levodopa?. <i>Nature Reviews Neurology</i> , 2014, 10, 488-489.	10.1	1
243	Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 523-526.	1.5	1
244	Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson's disease psychosis (PDP). <i>Parkinsonism and Related Disorders</i> , 2016, 22, e91-e92.	2.2	1
245	Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists. <i>CNS Drugs</i> , 2020, 34, 1267-1274.	5.9	1
246	Opicapone for Parkinson's disease: clinical evidence and future perspectives. <i>Neurodegenerative Disease Management</i> , 2021, 11, 193-206.	2.2	1
247	Strat?gies pharmacothe?rapeutiques actuelles et futures dans la prise en charge de la maladie de Parkinson. <i>Disease Management and Health Outcomes</i> , 2001, 9, 31-39.	0.4	1
248	Clinical Trials for in Parkinson's. <i>Neuromethods</i> , 2021, , 109-135.	0.3	1
249	Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome. <i>Integrative Medicine International</i> , 2014, 1, 32-43.	0.6	0
250	What Strategy Should France Implement for H2020?. <i>Therapie</i> , 2015, 70, 103-109.	1.0	0
251	PANDA: Prolonged release oxycodone/naloxone (OXN PR) for severe Parkinson's disease (PD)-related pain. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e101-e102.	2.2	0
252	Rotigotine for the Treatment of Advanced Parkinson's Disease. <i>European Neurological Review</i> , 2009, 4, 24.	0.5	0